UroGen Pharma Ltd Market Cap ($1.21 Billion)
Market Cap & Net Worth: UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd market cap. UroGen Pharma Ltd (NASDAQ:URGN) has a market capitalization of $1.21 Billion ($1.21 Billion) as of November 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7831 globally and #2349 in its home market, demonstrating a -26.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UroGen Pharma Ltd's stock price $24.75 by its total outstanding shares 48880564 (48.88 Million). Also see UroGen Pharma Ltd (URGN) cash flow conversion for how efficiently the company converts equity into cash flow.
UroGen Pharma Ltd Market Cap History (2017–2026)
UroGen Pharma Ltd market cap history from 2017 to 2026. Data shows growth from $1.82 Billion to $1.21 Billion (6.19% CAGR). Check UroGen Pharma Ltd share price for real-time trading data and today's change.
Index Memberships
UroGen Pharma Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.05% | #227 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.00% | #867 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.07% | #132 of 263 |
Weight: UroGen Pharma Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
UroGen Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UroGen Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore URGN net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
10.43x
UroGen Pharma Ltd's market cap is 10.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.82 Billion | $8.16 Million | -$20.00 Million | 222.95x | N/A |
| 2018 | $2.10 Billion | $1.13 Million | -$75.66 Million | 1865.95x | N/A |
| 2019 | $1.63 Billion | $18.00K | -$105.15 Million | 90619.13x | N/A |
| 2020 | $880.83 Million | $11.80 Million | -$128.48 Million | 74.65x | N/A |
| 2021 | $464.85 Million | $48.04 Million | -$110.82 Million | 9.68x | N/A |
| 2022 | $433.57 Million | $64.36 Million | -$109.78 Million | 6.74x | N/A |
| 2023 | $733.21 Million | $82.71 Million | -$102.24 Million | 8.86x | N/A |
| 2024 | $520.58 Million | $90.40 Million | -$126.87 Million | 5.76x | N/A |
| 2025 | $1.14 Billion | $109.79 Million | -$153.49 Million | 10.43x | N/A |
Competitor Companies of URGN by Market Capitalization
Companies near UroGen Pharma Ltd in the global market cap rankings as of November 7, 2026. Also see URGN asset base for a full breakdown of the balance sheet.
Key companies related to UroGen Pharma Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of UroGen Pharma Ltd (2017–2026)
Market capitalization of UroGen Pharma Ltd from 2017 to today. Between 2017 and today, UroGen Pharma Ltd's market cap moved from $1.82 Billion to $ 1.21 Billion, with a yearly change of 6.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.21 Billion | +5.68% |
| 2025 | $1.14 Billion | +119.91% |
| 2024 | $520.58 Million | -29.00% |
| 2023 | $733.21 Million | +69.11% |
| 2022 | $433.57 Million | -6.73% |
| 2021 | $464.85 Million | -47.23% |
| 2020 | $880.83 Million | -46.00% |
| 2019 | $1.63 Billion | -22.50% |
| 2018 | $2.10 Billion | +15.72% |
| 2017 | $1.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of UroGen Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.21 Billion USD |
| MoneyControl | $1.21 Billion USD |
| MarketWatch | $1.21 Billion USD |
| marketcap.company | $1.21 Billion USD |
| Reuters | $1.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more